INTELLIA THERAPEUTICS, INC. (NTLA) Total liabilities 2016–2025
INTELLIA THERAPEUTICS, INC. (NTLA) total liabilities at each fiscal year-end, per SEC filings.
$170.7MFY2025 · since FY2016: $89.1M → $170.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $170.7M | -46.5% |
| FY2024 | $319.1M | +27.2% |
| FY2023 | $250.8M | -11.9% |
| FY2022 | $284.5M | +11.9% |
| FY2021 | $254.2M | +70.3% |
| FY2020 | $149.3M | +131.8% |
| FY2019 | $64.4M | -7.2% |
| FY2018 | $69.4M | -8.3% |
| FY2017 | $75.6M | -15.1% |
| FY2016 | $89.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More NTLA financial trends
NTLA RevenueNTLA Net incomeNTLA Net marginNTLA Gross profitNTLA Gross marginNTLA Operating incomeNTLA Operating marginNTLA Operating cash flowNTLA Free cash flowNTLA Capital expendituresNTLA Return on equityNTLA Stock buybacksNTLA Dividends paidNTLA Total assetsNTLA Shareholders’ equityNTLA overview →